DR. LAURA EVE MAURER MD, MPH
Prescription History 1609305739
Internal Medicine in Chicago, IL

NPI Status: Active since June 12, 2017

Contact Information

211 E ONTARIO ST STE 1000
CHICAGO, IL
ZIP 60611
Phone: (312) 695-4147

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. LAURA EVE MAURER MD, MPH, an active Internal Medicine specialist practicing in Chicago, IL. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 137 documented patient claims. Among these therapy options, the most frequently utilized medication is Azelastine Hcl, which accounts for 69 claims alone.

Medication Index

No matching medications currently found on file.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Allergy/ Immunology
Provider Metrics Summary
Total Claims 69
30-Day Fills 97.5
Days Supply 2,730
IL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills50.4
Peer Average Days Supply1,456
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 109.1% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,143.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.56

State Avg Cost Per Claim

$47.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Allergy/ Immunology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IL State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills45.7
Peer Average Days Supply1,356
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,819.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$438.17

State Avg Cost Per Claim

$538.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Epinephrine

Generic Formulation: EpinephrineSpecialty: Allergy/ Immunology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 211
IL State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills17.3
Peer Average Days Supply303
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,484.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$290.39

State Avg Cost Per Claim

$288.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Allergy/ Immunology
Provider Metrics Summary
Total Claims 32
30-Day Fills 65.3
Days Supply 1,960
IL State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills84.4
Peer Average Days Supply2,522
Conservative Utilization

This provider writes prescriptions for this formulation 31.9% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $619.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.37

State Avg Cost Per Claim

$18.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Olopatadine Hcl

Generic Formulation: Olopatadine HclSpecialty: Allergy/ Immunology
Provider Metrics Summary
Total Claims 13
30-Day Fills 17.0
Days Supply 470
IL State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills23.9
Peer Average Days Supply627
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $418.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.22

State Avg Cost Per Claim

$56.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antihistamine used to treat itching and redness in the eyes due to allergies. This medication is not recommended for the treatment of eye irritation due to wearing contact lenses.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. LAURA EVE MAURER MD, MPH provides transparency into local medical care patterns within Chicago, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Internal Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.